# Efficacy and Safety of Sotagliflozin Versus Placebo in Chinese Patients With Type 2 Diabetes Mellitus Not Adequately Controlled by Metformin With or Without Sulfonylurea

Study · id `cardio:ct-nct03761134` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03761134](<https://clinicaltrials.gov/study/NCT03761134>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03761134

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 377 participants.

## Technical summary

Registry record NCT03761134. Randomized; double masking; primary purpose treatment. Start 2018-11-30 (actual); primary completion 2020-04-29 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 377 participants (enrolled count; ClinicalTrials.gov record NCT03761134, source copy `cardio:ctgov-nct03761134-2022-04-25`, retrieved 2026-10-26)
- Started: 2018-11-30 (actual) (ClinicalTrials.gov record NCT03761134, source copy `cardio:ctgov-nct03761134-2022-04-25`, retrieved 2026-10-26)
- Primary completion: 2020-04-29 (actual) (ClinicalTrials.gov record NCT03761134, source copy `cardio:ctgov-nct03761134-2022-04-25`, retrieved 2026-10-26)
- Completion: 2020-04-29 (actual) (ClinicalTrials.gov record NCT03761134, source copy `cardio:ctgov-nct03761134-2022-04-25`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT03761134, source copy `cardio:ctgov-nct03761134-2022-04-25`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "TERMINATED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03761134-2022-04-25`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy and Safety of Sotagliflozin Versus Placebo in Chinese Patients With Type 2 Diabetes Mellitus Not Adequately Controlled by Metformin With or Without Sulfonylurea
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): sotagliflozin (SAR439954)
- Intervention (Drug): placebo
- Intervention (Drug): metformin
- Intervention (Drug): sulfonylurea
- Lead sponsor: Sanofi
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Sanofi (`cardio:org-sanofi`)

## Provenance

Content hash: 83119ed06a83e5b9a4ee8166cb6d68ef04a447115774fc05880cf85fb57204c4
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
